Ignite Creation Date:
2024-05-06 @ 10:42 AM
Last Modification Date:
2024-10-26 @ 12:34 PM
Study NCT ID:
NCT03331848
Status:
WITHDRAWN
Last Update Posted:
2018-03-22
First Post:
2017-11-01
Brief Title:
Study to Evaluate the Efficacy Safety and Tolerability of PXT002331 Foliglurax in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinsons Disease Experiencing Motor Complications of Levodopa Therapy ATTUNED
Sponsor:
Prexton Therapeutics
Organization:
Prexton Therapeutics
Study Overview
Official Title:
A Multi-center Double-blind Randomized Placebo-controlled Parallel-arm Phase IIa Trial to Evaluate the Efficacy Safety and Tolerability of 8-week Oral Treatment With PXT002331 Foliglurax in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinsons Disease Experiencing Motor Complications of Levodopa Therapy ATTUNED
Status:
WITHDRAWN
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Business reasons
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATTUNED
Brief Summary:
This is a Multi-center Double-blind Randomized Placebo-controlled Parallel-arm Phase IIa proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing Motor Complications of Levodopa Therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None